BD (Becton, Dickinson, and Company) announced today the first self-collection, at-home HPV screening has been CE marked to the IVD directive 98/79/EC. With this new claim, diagnostic labs will now be able to process the self-collected vaginal samples using the BD Onclarity™ HPV Assay on either the BD COR™ System or the BD Viper™ LT. Dr. Jeff Andrews, VP of Global Medical Affairs at BD, states, “The goal of cervical cancer screening is simple but critical: to detect pre-cancer before it develops into cancer. Not only does self-collection afford women greater access to testing, but they may also feel confident that the reliability of HPV testing of self-collected samples is the same as if they went to a clinician.”
Read more here.
More on: News Regulatory